$10.46
+0.16 (+1.55%)
Open$10.40
Previous Close$10.30
Day High$10.54
Day Low$10.20
52W High$25.94
52W Low$18.85
Volume—
Avg Volume408.8K
Market Cap150.85M
P/E Ratio25.32
EPS$0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+129.3% upside
Current
$10.46
$10.46
Target
$23.98
$23.98
$18.55
$23.98 avg
$27.85
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 25.13M | 23.45M | 26.68M |
| Net Income | 5.79M | 5.38M | 7.18M |
| Profit Margin | 23.0% | 22.9% | 26.9% |
| EBITDA | 9.68M | 8.65M | 11.22M |
| Free Cash Flow | 5.88M | 4.59M | 6.09M |
| Rev Growth | +24.1% | -4.1% | +21.0% |
| Debt/Equity | 0.38 | 0.39 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |